Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

81.14 +0.78 (+0.98%)
Streaming Delayed Price Updated: 11:35 AM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Why Cytokinetics Stock Was a Nearly 5% Winner Today ↗
Via The Motley Fool
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
News headline image
Peering Into Cytokinetics's Recent Short Interest ↗
 
Via Benzinga
News headline image
(CYTK) - Analyzing Cytokinetics's Short Interest ↗
 
Via Benzinga
News headline image
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
News headline image
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study ↗
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024. 
Via Benzinga
News headline image
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024 ↗
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views ↗
 
Via Benzinga
Topics Earnings Stocks
News headline image
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Stocks Mixed Amid Flood Of Economic Data ↗
The Nasdaq is up triple digits midday, trading at fresh record highs thanks to Nvidia's post-earnings pop. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Falls Sharply; US Composite PMI Surges In May ↗
 
Via Benzinga
News headline image
Why Cytokinetics (CYTK) Shares Are Falling ↗
Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares. 
Via Benzinga
News headline image
Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
News headline image
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024 ↗
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.